Keytruda Granted Full Approval for MSI-H/dMMR Solid Tumors - Specialty Pharmacy Continuum
Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms | British Journal of Cancer
Pembrolizumab shows durable activity in subset of women with endometrial cancer
Merck & Co's Keytruda outperforms chemo in MSI-High colorectal cancer | pharmaphorum
Merck's KEYTRUDA® (pembrolizumab) Receives Two New Approvals in Japan
Pembrolizumab prolongs PFS vs. chemotherapy for certain patients with colorectal cancer
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors | Semantic Scholar
Approval of pembrolizumab (MSI-H/dMMR) and considerations for site-agnostic development of drugs in oncology
Pembrolizumab for dMMR/MSI-H tumors marks first tumor agnostic FDA approval | MDedge Hematology and Oncology
KEYNOTE-177 - Advanced MSI-H/dMMR Colorectal Cancer (CRC) - HCP
Frontiers | Biomarkers in Immunotherapy-Based Precision Treatments of Digestive System Tumors
FDA Grants Full Approval to Pembrolizumab for Select Patients With MSI-H or dMMR Solid Tumors
Keytruda (pembrolizumab) for the Treatment of Metastatic Melanoma
Pembrolizumab (Keytruda) Drug Information
Pembrolizumab Considered for Second Tissue-Agnostic Cancer Indication - ILCN.org (ILCN/WCLC)
Best PSA response on pembrolizumab in men with MMRd/MSI-H PC. Best %... | Download Scientific Diagram
FDA Converts to Full Approval Indication for KEYTRUDA® (pembrolizumab) for Certain Adult and Pediatric Patients With Advanced Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Solid Tumors | Business Wire
Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer | NEJM
Pembrolizumab for Advanced MSI-H/dMMR Cancers
Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H)
ESMO 2022: Pembrolizumab in microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) advanced solid tumors: An update of the phase II KEYNOTE-158 trial
Partners in Progress: Cancer Patient Advocates and FDA Public Workshop
Microsatellite instability and immune checkpoint inhibitors: toward precision medicine against gastrointestinal and hepatobiliary cancers | SpringerLink
Keytruda doubled survival in advanced colon cancer compared to chemo' < Pharma < Article - KBR
High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer | Scientific Reports
Pembrolizumab Shows Continued PFS Benefit in MSI-H/dMMR Metastatic Colorectal Cancer
First-Line Pembrolizumab Versus Chemotherapy in Patients
Advanced MSI-H/dMMR Colorectal Cancer | KEYTRUDA® (pembrolizumab) | Patients
